

## Amniotics Q4 2022 - Our Comments

Redeye comments on the events of the fourth quarter, including progress with the main candidate PulmoStem and the rights issue.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.

### Attachments

---

[Amniotics Q4 2022 - Our Comments](#)